Notes for Editors Deltex Medical manufactures and markets haemodynamic monitoring technologies which are primarily used in critical care and general surgical procedures. Deltex Medical s proprietary oesophageal Doppler monitoring ( ODM ) (TrueVue Doppler) measures blood flow velocity in the central circulation in real time. Minimally invasive, easy to set-up and quick to focus, the technology generates a low-frequency ultrasound signal which is highly sensitive to changes in blood flow and measures such changes in real time . Deltex Medical is the only company in the enhanced haemodynamic space to have built a robust and credible evidence base demonstrating both the clinical and economic benefits of its core technology: TrueVue Doppler. This technology has been proven in a wide range of clinical trials to reduce complications suffered by patients after surgery and consequently can save hospitals money.
20 January 2021 | 14:06pm
StockMarketWire.com - Deltex Medical Group s recorded revenues of £2.4 million in 2020, roughly half of the amount recorded by the medical technology company in 2019.
In 2019, Deltex Medical registered revenue of £4.3 million.
For 2020, cash at hand was the same as the year before at £900,000.
These figures reflect the 12 months up to the end of the year.
The company as also appointed Professor Tim Irish to its board with immediate effect.
Joining as a director, Irish has worked in the life sciences industry for 30 years.
Deltex Medical Group chairman Nigel Keen said: I am very pleased to welcome Tim Irish back to the Board. He brings with him great experience in medical device businesses coupled with insights into the way that the NHS adopts new technologies gained from his time as Vice-Chair of NICE.
A
Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient: 1. Obtains access to the information in a personal capacity; 2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services; 3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body; 4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
LONDON TRADING UPDATES: Alliance Pharma 2020 Revenue Slips By 5%
Wed, 20th Jan 2021 17:40
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:
Alliance Pharma PLC - healthcare company - Expects see-through revenue for 2020 to be down 5% on the prior year at GBP137.5 million from GBP144.3 million reported for 2019, both on a reported basis and on a constant currency basis, reflecting the impact of the Covid-19 pandemic. Underlying pretax profit for 2020 is expected to be marginally ahead of market expectations. As we progress into 2021, we look forward to regaining the strong momentum and revenue growth of recent years, and to benefiting from the additional growth opportunities that Amberen brings into the group, said Chief Executive Peter Butterfield. The acquisition of Biogix has brought Amberen into Alliance Pharma, a brand for the relief of menopause symptoms. The acquisition cre